Medicine and Dentistry
Rituximab
66%
Cancer Registry
66%
5 Hydroxymethylcytosine
66%
Etoposide
66%
Acute Myeloid Leukemia
66%
Diseases
46%
Targeted Therapy
33%
Peripheral T-Cell Lymphoma
33%
Cyclophosphamide
33%
Prednisone
33%
Lymphomatoid Granulomatosis
33%
Chronic Myelomonocytic Leukemia
33%
Central Nervous System
33%
Cell-Free DNA
33%
Doxorubicin
33%
Vincristine
33%
Cancer
33%
T Cell
33%
Coronary Sinus
33%
Myeloproliferative Neoplasm
33%
Primary Central Nervous System Lymphoma
33%
Burkitt's Lymphoma
33%
Idiopathic Thrombocytopenic Purpura
33%
Romidepsin
33%
Breast Cancer
33%
Multiple Myeloma
33%
Disease Assessment
33%
Ifosfamide
33%
Brentuximab Vedotin
33%
Imatinib
33%
Minimal Residual Disease
33%
Diffuse Large B-Cell Lymphoma
33%
Human Epidermal Growth Factor Receptor 2 Positive Breast Cancer
33%
Carboplatin
33%
Overall Survival
30%
Neoplasm
27%
Disease Specific Survival
25%
Systemic Therapy
23%
Surgery
22%
Philadelphia 1 Chromosome
16%
Acute Lymphoblastic Leukemia
16%
Angioimmunoblastic T-Cell Lymphoma
16%
Myeloid metaplasia
16%
Essential Thrombocythaemia
16%
Odds Ratio
14%
Chronic Myelogenous Leukemia
11%
Diagnostic Testing
11%
Eosinophilia
11%
Diagnosis
11%
Magnetic Resonance Imaging
11%
Keyphrases
Etoposide
66%
Peripheral T-cell Lymphoma
33%
Coronary Sinus
33%
Emerging Markers
33%
Confidence Interval
33%
Cyclophosphamide
33%
Relapsed or Refractory
33%
Prednisone
33%
PDGFRA mutation
33%
FIP1L1-PDGFRA
33%
Leukemia Transformation
33%
Minimal Residual Disease
33%
Rituximab
33%
Acute Myeloid Leukemia
33%
5-hydroxymethylcytosine (5hmC)
33%
Older Patients
33%
Primary Central Nervous System Lymphoma (PCNSL)
33%
Romidepsin
33%
Cell-free DNA (cfDNA)
33%
Disease Assessment
33%
Brentuximab Vedotin
33%
Ifosfamide
33%
Doxorubicin
33%
Carboplatin
33%
CD30
33%
Diffuse Large B-cell Lymphoma (DLBCL)
33%
Texas Cancer Registry
33%
Highly Sensitive
33%
Primary Cardiac Lymphoma
16%
Natural Disease Course
16%
Leukemia Patients
14%
Staging Investigations
11%
San Antonio Breast Cancer Symposium
11%
Cardiotoxicity
8%
Treatment Methods
8%
Perforation
8%
Risk Reduction
8%
R-CHOP
8%
Anthracyclines
8%
Clinical Practice Guidelines
8%
One-cycle
8%
Clinical Entities
8%
Continuous Infusion
8%
Young Males
8%
Disease-specific Survival
7%
Chemotherapy
7%
Poor Prognosis
6%
Poverty Measures
6%
Pharmacology, Toxicology and Pharmaceutical Science
Acute Myeloid Leukemia
100%
5 Hydroxymethylcytosine
100%
Etoposide
66%
Carboplatin
33%
Prednisone
33%
Chronic Myelomonocytic Leukemia
33%
Doxorubicin
33%
Cyclophosphamide
33%
Brentuximab Vedotin
33%
Rituximab
33%
Peripheral T Cell Lymphoma
33%
Primary Central Nervous System Lymphoma
33%
Romidepsin
33%
Vincristine
33%
Diffuse Large B Cell Lymphoma
33%
Cancer Registry
33%
Minimal Residual Disease
33%
Ifosfamide
33%
Overall Survival
20%
Disease Specific Survival
11%
Chemotherapy
11%
Cyclophosphamide Plus Doxorubicin Plus Prednisolone Plus Rituximab Plus Vincristine
8%
Diseases
8%
Cardiotoxicity
8%
Anthracycline
8%
Leukemia
6%
Nonhodgkin Lymphoma
5%
Malignant Neoplasm
5%
